431 related articles for article (PubMed ID: 20049846)
61. Src activation by β-adrenoreceptors is a key switch for tumour metastasis.
Armaiz-Pena GN; Allen JK; Cruz A; Stone RL; Nick AM; Lin YG; Han LY; Mangala LS; Villares GJ; Vivas-Mejia P; Rodriguez-Aguayo C; Nagaraja AS; Gharpure KM; Wu Z; English RD; Soman KV; Shahzad MM; Zigler M; Deavers MT; Zien A; Soldatos TG; Jackson DB; Wiktorowicz JE; Torres-Lugo M; Young T; De Geest K; Gallick GE; Bar-Eli M; Lopez-Berestein G; Cole SW; Lopez GE; Lutgendorf SK; Sood AK
Nat Commun; 2013; 4():1403. PubMed ID: 23360994
[TBL] [Abstract][Full Text] [Related]
62. AGO2 phosphorylation by c-Src kinase promotes tumorigenesis.
Liu T; Zhang H; Fang J; Yang Z; Chen R; Wang Y; Zhao X; Ge S; Yu J; Huang J
Neoplasia; 2020 Mar; 22(3):129-141. PubMed ID: 31981897
[TBL] [Abstract][Full Text] [Related]
63. Novel oncoprotein EPS8: a new target for anticancer therapy.
Li YH; Xue TY; He YZ; Du JW
Future Oncol; 2013 Oct; 9(10):1587-94. PubMed ID: 24106906
[TBL] [Abstract][Full Text] [Related]
64. [Role of vimentin in tumor metastasis and drug research].
Pan Y; Han J; Zhang Y; Li XJ
Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):413-6. PubMed ID: 21416957
[TBL] [Abstract][Full Text] [Related]
65. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen T; George JA; Taylor CC
Anticancer Drugs; 2006 Feb; 17(2):123-31. PubMed ID: 16428929
[TBL] [Abstract][Full Text] [Related]
66. Implications for Src kinases in hematopoiesis: signal transduction therapeutics.
Sinha S; Corey SJ
J Hematother Stem Cell Res; 1999 Oct; 8(5):465-80. PubMed ID: 10791898
[TBL] [Abstract][Full Text] [Related]
67. Caspase-8 expression and its Src-dependent phosphorylation on Tyr380 promote cancer cell neoplastic transformation and resistance to anoikis.
Fianco G; Cenci C; Barilà D
Exp Cell Res; 2016 Sep; 347(1):114-122. PubMed ID: 27432652
[TBL] [Abstract][Full Text] [Related]
68. Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.
Park SI; Shah AN; Zhang J; Gallick GE
Expert Opin Ther Targets; 2007 Sep; 11(9):1207-17. PubMed ID: 17845146
[TBL] [Abstract][Full Text] [Related]
69. Recent progress of SRC family kinase inhibitors as anticancer agents.
Cao X; You QD; Li ZY; Wang XJ; Lu XY; Liu XR; Xu D; Liu B
Mini Rev Med Chem; 2008 Sep; 8(10):1053-63. PubMed ID: 18782057
[TBL] [Abstract][Full Text] [Related]
70. Role of co- and post-translational modifications of SFKs in their kinase activation.
Cai ML; Wang MY; Zhang CH; Wang JX; Liu H; He HW; Zhao WL; Xia GM; Shao RG
J Drug Target; 2020 Jan; 28(1):23-32. PubMed ID: 31094236
[TBL] [Abstract][Full Text] [Related]
71. SRC Signaling in Cancer and Tumor Microenvironment.
Caner A; Asik E; Ozpolat B
Adv Exp Med Biol; 2021; 1270():57-71. PubMed ID: 33123993
[TBL] [Abstract][Full Text] [Related]
72. Src: regulation, role in human carcinogenesis and pharmacological inhibitors.
Tsygankov AY; Shore SK
Curr Pharm Des; 2004; 10(15):1745-56. PubMed ID: 15180537
[TBL] [Abstract][Full Text] [Related]
73. SRC: a century of science brought to the clinic.
Aleshin A; Finn RS
Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
[TBL] [Abstract][Full Text] [Related]
74. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.
Lieu C; Kopetz S
Clin Colorectal Cancer; 2010 Apr; 9(2):89-94. PubMed ID: 20378502
[TBL] [Abstract][Full Text] [Related]
75. Src-family tyrosine kinases as therapeutic targets in advanced cancer.
Gelman IH
Front Biosci (Elite Ed); 2011 Jun; 3(3):801-7. PubMed ID: 21622091
[TBL] [Abstract][Full Text] [Related]
76. Src-family Protein Tyrosine Kinases: A promising target for treating Cardiovascular Diseases.
Zhai Y; Yang J; Zhang J; Yang J; Li Q; Zheng T
Int J Med Sci; 2021; 18(5):1216-1224. PubMed ID: 33526983
[TBL] [Abstract][Full Text] [Related]
77. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?
Susva M; Missbach M; Green J
Trends Pharmacol Sci; 2000 Dec; 21(12):489-95. PubMed ID: 11121839
[TBL] [Abstract][Full Text] [Related]
78. Redox circuitries driving Src regulation.
Giannoni E; Chiarugi P
Antioxid Redox Signal; 2014 May; 20(13):2011-25. PubMed ID: 23901911
[TBL] [Abstract][Full Text] [Related]
79. Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer.
Barneh F; Mirzaie M; Nickchi P; Tan TZ; Thiery JP; Piran M; Salimi M; Goshadrou F; Aref AR; Jafari M
Brief Bioinform; 2019 Mar; 20(2):717-731. PubMed ID: 29726962
[TBL] [Abstract][Full Text] [Related]
80. Coupling kinase activation to substrate recognition in SRC-family tyrosine kinases.
Pellicena P; Miller WT
Front Biosci; 2002 Jan; 7():d256-67. PubMed ID: 11779710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
